Example: Heart Attack

Clinical Trials on Borderline Resectable Adenocarcinoma of the Head of the Pancrease

Total 9779 results

NCT01623596

Completed

Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. (PREFERMS)

Relapsing Remitting Multiple Sclerosis
NCT02117375

Unknown

EMISEP : Early Spinal Cord Lesions and Late Disability in Relapsing Remitting Multiple Sclerosis Patients (EMISEP)

Multiple Sclerosis
NCT01450124

Completed

Safety, Tolerability And Mechanism Of Action Of Boswellic Acids (BA) In Multiple Sclerosis (SABA) (SABA)

Relapsing Remitting Multiple Sclerosis
NCT02533882

Completed

Lakeshore Examination of Activity and Disability Exercise Response Study (LEADERS)

Stroke | Multiple Sclerosis
NCT03108950

Completed

From Clinic to Community: An Information and Communication Technology (ICT) Home-Based Exercise Training System for Translating Clinical Findings (TExT-ME)

Stroke | Multiple Sclerosis
NCT02885831

Unknown

Early Abduction Splintage on Stable Hips in Infants With Developmental Dysplasia of the Hip (BBH)

Congenital Hip Dysplasia
NCT01667796

Completed

Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health

Multiple Sclerosis, Relapsing-remitting
NCT00645749

Completed

Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis (HINT)

Relapsing Remitting Multiple Sclerosis
NCT01307332

Completed

Advanced MRI Measures of Repair in Alemtuzumab Treated Patients (iCAMMS-IST)

Relapsing Remitting Multiple Sclerosis
NCT00939549

Withdrawn

High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis (HiCy)

Relapsing Remitting Multiple Sclerosis
NCT02254304

Completed

Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™ (PROCEED)

Clinically Isolated Syndrome | Relapsing Multiple Sclerosis
NCT02638038

Completed

This is a Randomized Study Comparing Two Doses of INT131 ( 3 mg and 1 mg) Administered Orally (PO) Daily (QD) Versus Placebo 1 Tablet PO QD in Subjects With Treatment-naïve RRMS for ≤ 3 Years

Multiple Sclerosis, Relapsing Remitting
NCT02474940

Completed

MS Symptom Management Study (ENHANCE)

Multiple Sclerosis | Fatigue | Chronic Pain
NCT01631331

Completed

Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC)

Recurrent Skin Cancer | Basal Cell Carcinoma of the Skin
NCT02247310

Completed

BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon

Multiple Sclerosis, Relapsing Remitting
NCT01767701

Completed

Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis (INSPIRE)

Relapsing Remitting Multiple Sclerosis
NCT00981643

Completed

Effects of Meditation on Multiple Sclerosis and Peripheral Neuropathy

Multiple Sclerosis | Peripheral Neuropathy
NCT01489254

Completed

Efficacy and Safety of GTR in Comparison to Copaxone® (GATE)

Multiple Sclerosis
NCT01808885

Completed

Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta. (MSREPAIR)

Relapsing Remitting Multiple Sclerosis
NCT01717664

Completed

Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS) (CEASE-MS)

Relapsing Remitting Multiple Sclerosis
NCT00451204

Completed

A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS) (Estriol-MS)

Relapsing Remitting Multiple Sclerosis
NCT01755871

Terminated

Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis (BiobankII)

Relapsing Remitting Multiple Sclerosis
NCT01963611

Terminated

Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)

Relapsing Remitting Multiple Sclerosis
NCT01317004

Completed

Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change (EPOC)

Relapsing Remitting Multiple Sclerosis
NCT00056810

Completed

Assessment of Chronic Guillain-Barre Syndrome Improvement With Use of 4-aminopyridine

Guillain-Barre Syndrome
NCT01655394

Unknown

Change of Nerve Conduction Properties in IVIg Dependent Neuropathies

Guillain-Barre Syndrome | CIDP | Multifocal Motor Neuropathy
NCT01534182

Completed

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC) (EPOC)

Relapsing Remitting Multiple Sclerosis
NCT01080027

Completed

Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR) (STAR)

Multiple Sclerosis, Relapsing Remitting
NCT00211887

Completed

Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx

Relapsing Remitting Multiple Sclerosis
NCT00097188

Completed

A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis

Multiple Sclerosis
NCT00367484

Completed

Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis

Relapsing Remitting Multiple Sclerosis
NCT01081782

Completed

A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis (DreaMS)

Multiple Sclerosis
NCT01167426

Completed

Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients (ENCORE)

Multiple Sclerosis
NCT01464905

Unknown

Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Relapsing Remitting Multiple Sclerosis
NCT01906684

Unknown

Comprehensive Analysis of Relapse in Multiple Sclerosis

Multiple Sclerosis
NCT01065727

Unknown

Impact Study of 2 Therapeutic Strategy for Aggressive Remitting Multiple Sclerosis (IQUALYSEP)

Multiple Sclerosis
NCT00206635

Completed

Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis
NCT01705457

Unknown

Impact of Vitamin A on RAR Gene Expression in Multiple Sclerosis (RAR)

Relapsing Remitting Multiple Sclerosis
NCT00337779

Completed

Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).

Relapsing Remitting Multiple Sclerosis
NCT01273935

Completed

Dose-Dependent Effect of Early Antiplatelet Therapy in Acute Ischemic Stroke

Test the Efficacy of Antiplatelet Regimes in Acute Stroke
NCT01020370

Completed

Exploratory Study to Investigate the Reparative and Regenerative Potential of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Participating in the CARE MS I and MS II Studies

Multiple Sclerosis
NCT03180684

Completed

Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)

Human Papillomavirus (HPV) | Vulvar Dysplasia | Vulvar Intraepithelial Neoplasia (VIN) | Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) | VIN2 | VIN3 | Pre-cancerous Lesions of the Vulva
NCT00053209

Completed

Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer
NCT00002914

Completed

Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer
NCT03604991

Suspended

Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery

Esophageal Adenocarcinoma | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Gastroesophageal Junction Adenocarcinoma | Clinical Stage II Esophageal Adenocarcinoma AJCC v8 | Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8 | Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
NCT06324734

Completed

Assessment of Safety of Olaparib in Chinese Patients With Ovarian Cancer in the Real-World Setting

Using NCID Database to Assess the Safety of Olaparib in Chinese Patients With Ovarian Cancer by Examining the Incidence, Seriousness, and Severity of All AE
NCT00004223

Completed

Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer
NCT04717765

Completed

Photobiomodulation in Oral Lesions Resulting From Anti-neoplastic Prevention

Head and Neck Cancer | Oral Cancer | Oral Mucositis | Osteoradionecrosis | Hyposalivation | Osteonecrosis Due to Drugs, Jaw | Osteonecroses, Bisphosphonate
NCT05059444

Recruiting

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation (ORACLE)

Renal Cell Carcinoma | Pancreatic Adenocarcinoma | Gastric Adenocarcinoma | Squamous Cell Carcinoma of the Head and Neck | Non-small Cell Lung Cancer | Fallopian Tube Carcinoma | Endometrial Carcinoma | Bladder Carcinoma | Esophageal Carcinoma | Invasive Breast Carcinoma
NCT02443324

Completed

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Carcinoma, Transitional Cell | Gastric Adenocarcinoma | Non-small Cell Lung Cancer | Biliary Tract Cancer | Adenocarcinoma of the Gastroesophageal Junction

Clinical Trials on Borderline Resectable Adenocarcinoma of the Head of the Pancrease

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations